MSC Biotarget LLC
An early stage drug development company.
Tuesday February 28,2012
The Park Avenue Club, Florham Park, New Jersey (directions)
|
About
|
MSC Biotarget LLC is developing a class of medicinal substances that have the potential to be transformative innovations in the treatment of cancer. These proprietary compounds have significant therapeutic and economic potential for the following reasons: (1) these compounds kill cancer cells without harming healthy cells; (2) these compounds appear to be effective, safe and economical for a broad range of cancers; (3) the potential regulatory pathways – orphan drug and botanical drug – reduce the steps necessary for approval and commercialization thereby significantly reducing financial risk and raising the probability of successful commercialization; and (4) one drug candidate is ready to enter the clinical trial process.
MSC Biotarget initiated a drug development program with Cold Spring Harbor Laboratory (CSHL) that resulted in the identification of several drug candidates based on fermented wheat germ extract (FWGE). We are now preparing to file an IND on an anti-metastatic botanical drug that we call A250. Later this year, we plan to start Phase I clinical trials in ovarian cancer which is an orphan disease indication. A very large, US based gynecological oncology practice has expressed an interest in hosting this clinical trial.
The financial risks of drug development and clinical trials for A250 are very low compared to other oncology drug candidates because our strategy is to seek FDA approval as a “botanical drug” and ovarian cancer is an orphan disease indication.
The A250 research and development collaboration team is experienced and accomplished. The team includes Nobel Laureate, Dr. James Watson and CSHL researchers Dr. Nicholas Tonks, and Darryl Pappin, Dr. Mate Hidvegi, inventor of Avemar FWGE and Dr. Gyorgy Keri, and Dr. Laszlo Orfi, co-inventors of the block buster cancer drug Sutent (Sunitinib).
MSC Biotarget has the exclusive license to patents on utility and composition related to A250 that were filed in August of 2011. A250 is a well characterized substance and the manufacturing process produces a precisely standardized product. We have a manufacturing partner willing to invest in scale-up costs, and we are in the process of raising $10 million (in one or more tranches) to complete Phase I and II clinical trials. We are looking for distribution partners for A250 once it is approved as an oncology drug. Depending upon the final strategic marketing plan, we could also market A250 as a food and/or dietary supplement that would further lower the financial risk to our investors.
3 Major Issues
|
-
1. How do we set ourselves apart from all of the other experimental therapies that we are competing with for investment?
-
Who is the most important individual we need to bring into the team: (a) supervisor of clinical trials; or, (b) manager of the commercialization and licensing of our approved drugs and drug candidates? What would be the purpose of hiring a CEO and what would that person do?
-
Given our status as a drug development company, what type of investor is best suited to fill our needs: angel investor, venture capitalist, or pharmaceutical company?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - David Wales and Rick Jahnke, co-founders of MSC Biotarget, will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
Reserve your dinner for this month's meeting online now though PayPal.
Please note: You do not need a PayPal account to reserve your spot, most credit cards are accepted.
|
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
